Clinical Trial Update: Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction [Phase 1]

View source ↗

Summary

Pfizer-sponsored Phase 1 trial of irinotecan in patients with refractory solid tumors and liver dysfunction has completed, providing safety and dosing informati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Dysfunction
• Solid Tumors

Drugs mentioned

• Irinotecan (Irinotecan)

Snippet

Sponsor: Pfizer | Conditions: Unspecified Adult Solid Tumor, Chemotherapy | Phase 1 | Status: COMPLETED